bluebird bio

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Bluebird bio reports strong financials and plans for expansion

Bluebird bio demonstrated financial strength and successful gene therapy launches.
Challenges include potential submission delay and operational complexities.
Opportunities lie in expanding patient demand, optimizing strategies, and exploring international markets.
Overall, Bluebird bio remains confident in its products and market positioning.

Bluebird bio excels in gene therapy market, faces manufacturing challenges

Bluebird bio is making significant strides in gene therapy, with successful commercial launches and a strong financial position.
Challenges lie in adapting to a different manufacturing process for lovo-cel and ensuring operational efficiency for future launches.
Opportunities abound in expanding commercial reach, leveraging expertise for targeted launches, and strategic decision-making on PRV monetization.

Bluebird bio reports revenue growth and milestones in Q3

Bluebird bio's Q3 performance showed revenue growth and positive momentum in key product launches.
The company faces challenges related to safety concerns, manufacturing issues, and analyst inquiries.
Strengths lie in a well-established commercial infrastructure and strategic pricing approach.
Opportunities include financing plans, potential voucher sale, and expansion of treatment centers.

bluebird bio reports revenue growth and eyes U.S. expansion opportunities

bluebird bio's Q4 performance showed revenue growth and extended cash runway
Strengths lie in commercial progress, multibillion-dollar U.S. opportunity, and margin improvement
Challenges include financial restatement, reimbursement dynamics, and Medicaid coverage
Opportunities exist in ex U.S. markets, expansion plans, and optimizing reimbursement strategies

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your bluebird investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors

bluebird bio Inc (NASDAQ:BLUE), the gene therapy developer, is well-positioned to outperform pessimistic expectations regarding the launch of its Lyfgenia treatment. Shares fell close to 70% in December, and analysts at Baird believe much of the negative sentiment surrounding the stock is due to disappointment by the lack of Lyfgenia cell collections.

Bluebird biotech set to outperform pessimistic expectations – broker

NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of bluebird bio, Inc. ("bluebird bio") (NASDAQ:BLUE) concerning possible violations of federal securities laws. On December 8, 2023, BLUE announced that the Food and Drug Administration (FDA) approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).

bluebird bio Being Investigated on Behalf of bluebird bio, Inc. Investors. Contact Levi & Korsinsky For Details.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On March 26, 2024, bluebird announced that it will restate financial statements for 2022 and for the first three quarters of both 2022 and 2023 in relation to the identifica.

The Law Offices of Frank R. Cruz Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors

bluebird bio (BLUE) revenues miss the Zacks Consensus Estimate in the fourth quarter. The company progresses with the launch of its three approved gene therapies.

bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates

Did bluebird bio, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - BLUE

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of bluebird bio Inc. (NASDAQ: BLUE) resulting from allegations that bluebird may have issued materially misleading business information to the investing public. SO WHAT: If you purchased bluebird securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

BLUE LOSS ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline

Shareholder Rights Advocates at Levi & Korsinsky Investigate bluebird bio, Inc. (BLUE) Regarding Possible Securities Fraud Violations

LOS ANGELES, CA / ACCESSWIRE / March 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of bluebird bio, Inc. ("bluebird" or "the Company") (NASDAQ:BLUE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses to Contact the Firm

bluebird bio, Inc. (BLUE) Q4 2023 Earnings Call Transcript

NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of bluebird bio, Inc. ("bluebird bio") (NASDAQ:BLUE) concerning possible violations of federal securities laws. On December 8, 2023, BLUE announced that the Food and Drug Administration (FDA) approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).

bluebird bio, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - BLUE

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported fourth quarter and annual financial results and business highlights for the year ended December 31, 2023, including recent commercial and operational progress. “In 2023, bluebird established a validated, commercial gene therapy strategy that brought ZYNTEGLO and SKYSONA to individuals living with beta-thalassemia and cerebral adrenoleukodystrophy. Building on that foundation, t.

bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss fourth quarter and 2023 annual results and business updates on March 26, 2024, at 8:00 a.m. ET. To access the live conference call via telephone, please register at this link to receive a dial in number and unique PIN. The live webcast of the call may be accessed by visiting the “Events & Presentations” page within the Investors & Media section of the blue.

bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call

NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of bluebird bio, Inc. ("bluebird bio") (NASDAQ:BLUE) concerning possible violations of federal securities laws. On December 8, 2023, BLUE announced that the Food and Drug Administration (FDA) approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).

Lost Money on bluebird bio, Inc.(BLUE)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of bluebird bio, Inc. ("bluebird bio") (NASDAQ:BLUE) concerning possible violations of federal securities laws. On December 8, 2023, BLUE announced that the Food and Drug Administration (FDA) approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).

bluebird bio, Inc. (BLUE) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

bluebird (BLUE) obtains a $175 million five-year, term loan facility from Hercules that stretches its cash runaway by two years. The company's shares rise on the news.

bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up

The commercial-stage biotech has secured a nine-figure loan facility. This potentially gives it access to as much as $175 million in debt funding.

Why Bluebird Bio Stock Flew Higher Than the Market Today

Hercules Capital

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a $175 million five-year, term loan facility with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”). The transaction strengthens the Company's balance sheet as it executes on the commercial launches for its three FDA approved gene therapies – LYFGENIA for sickle cell disease, ZYNTEGLO for beta-thalassemia and SKYSONA for cerebral adrenoleukodystrophy. T.

bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital

NEW YORK, NY / ACCESSWIRE / March 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of bluebird bio, Inc. ("bluebird bio") (NASDAQ:BLUE) concerning possible violations of federal securities laws. On December 8, 2023, BLUE announced that the Food and Drug Administration (FDA) approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).

bluebird bio Being Investigated on Behalf of bluebird bio, Inc. Investors. Contact Levi & Korsinsky For Details

Bluebird Bio has three gene-editing products on the market. However, it will face issues delivering these therapies to patients.

Is Bluebird Bio Stock a Buy Now?

NEW YORK, NY / ACCESSWIRE / March 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of bluebird bio, Inc. ("bluebird bio") (NASDAQ:BLUE) concerning possible violations of federal securities laws. On December 8, 2023, BLUE announced that the Food and Drug Administration (FDA) approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).

BLUE ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of bluebird bio, Inc. Shareholders Who Lost Money

NEW YORK, NY / ACCESSWIRE / March 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of bluebird bio, Inc. ("bluebird bio") (NASDAQ:BLUE) concerning possible violations of federal securities laws. On December 8, 2023, BLUE announced that the Food and Drug Administration (FDA) approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).

ATTENTION bluebird bio, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio”) today announced it has signed its first Medicaid outcomes-based agreement for LYFGENIA™ (lovotibeglogene autotemcel, also known as lovo-cel) with the state of Michigan. LYFGENIA is a one-time gene therapy approved for the treatment of patients 12 years of age and older with sickle cell disease and a history of vaso-occlusive events (VOEs). Approximately 50 percent of individuals living with sickle cell diseas.

bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy

NEW YORK, NY / ACCESSWIRE / March 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of bluebird bio, Inc. ("bluebird bio") (NASDAQ:BLUE) concerning possible violations of federal securities laws. On December 8, 2023, BLUE announced that the Food and Drug Administration (FDA) approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).

News for bluebird bio Stock (BLUE)